Upgrade to BuyandBill.com Pro to access this report and the complete suite of analytics tools.
| Manufacturer ▼ | Drug Name | Indication | Stage | Status | Route of Administration | Drug Class |
|---|---|---|---|---|---|---|
| Repare Therapeutics Inc. | Camonsertib (RP-3500)/ RG6526)- (TRESR) | Solid Tumors | Phase 2 | Data Released | oral | Oncology |
| Replimune Group Inc. | RP1 (vusolimogene oderparepvec) and OPDIVO (nivolumab) - (IGNYTE-3) | Non-melanoma (NMSC) / Non-small cell lung cancer (NSCLC) | PDUFA | Ongoing | intratumoral and intravenous | Oncology |
| Replimune Group Inc. | RP2-202 - (REVEAL) | Uveal melanoma | Phase 2/3 | Enrollment Initiation | Intravenous | Oncology |
| Replimune Group Inc. | RP2-003 with atezolizumab and bevacizumab | Hepatocellular Carcinoma | Phase 2 | Enrollment Initiation | Intravenous | Oncology |
| Replimune Group Inc. | INCB99280 | High risk resectable cutaneous squamous cell carcinoma (CSCC) | Phase 2 | Trial Planned | oral | Oncology |
| Revelation Biosciences Inc. | REVTx-99 | H3N2 Influenza | Phase 2b | Trial Discontinued | Intranasal | Antiviral |
| Revelation Biosciences Inc. | REVTx-200 | Prevention and/or treatment of respiratory viral infection | Phase 2 | Ongoing | Intranasal | Respiratory |
| Reviva Pharmaceuticals Holdings Inc. | Brilaroxazine - (RECOVER-2) | Schizophrenia | Phase 3 | Trial Planned | Oral | Psychiatric |
